Vyome Holdings, Inc., a clinical-stage specialty pharmaceutical company, develops therapeutic products targeting immuno-inflammatory and rare diseases in the United States. It operates through Pharmaceutical and Biotechnology segments. The company's lead product candidate VT-1953, a dual DNA Gyrase/Topoisomerase inhibitor and immunomodulator in a topical gel formulation that is in phase 2 clinical stage for the treatment of bacterial conjunctivitis. It also develops VT-1908, a topical eye drop is an inosine 5'-monophosphate dehydrogenase enzyme inhibitor to treat immunoinflammatory conditions of the eye; and VB-1953, which is in phase 2 clinical stage for the treatment of inflammatory acne. In addition, the company develops antifungal products using the molecular replacement therapy (MRT) platform. It has a collaboration and license agreement with Sun Pharma Laboratories Limited to develop and commercialize next-generation antifungal products. The company is based in Cambridge, Massachusetts.
Frequently asked questions
What sector does Vyome Holdings, Inc. (HIND) operate in?
Vyome Holdings, Inc. belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Vyome Holdings, Inc. (HIND) current stock price?
As of the latest data, Vyome Holdings, Inc. stock price is $1.70, with a previous close of $1.71. Vyome Holdings, Inc. lost -$0.02 in the last trading session, representing a -0.88% loss.
What is Vyome Holdings, Inc. (HIND) current market capitalization?
Vyome Holdings, Inc. market cap is approximately 11.90 million.
What is Vyome Holdings, Inc. (HIND) Earnings Per Share (EPS)?
The trailing EPS is -$1.61, and the forward EPS is -$0.80.
What is Vyome Holdings, Inc. (HIND) EBITDA?
Vyome Holdings, Inc. EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -713.75 thousand.
Does Vyome Holdings, Inc. (HIND) pay dividends?
No. Vyome Holdings, Inc. does not pay a dividend.
When is Vyome Holdings, Inc. (HIND) next earnings report?
Vyome Holdings, Inc. is expected to release its next earnings report on September 30, 2026.
What is Vyome Holdings, Inc. (HIND) beta (volatility) score?
Vyome Holdings, Inc. has a beta of 2.015, indicating very high volatility compared to the market.
